DexCom Inc at William Blair Growth Stock Conference Transcript
Hey, good morning, everyone. Thanks for joining us. My name is Margaret Kaczor, and I am the research analyst here at William Blair & Company who covers DexCom.
Now before we begin, I am required to inform you that I personally own shares of DexCom. But beyond that, you can obtain a complete list of research disclosures or potential conflicts of interest at williamblair.com.
I'll do a short introduction then we'll kind of drive over to Q&A. But DexCom has been one of the top-performing stocks on our coverage universe over the last -- now 3 years probably. And despite the years of strong growth, sales continue to accelerate in spite of competition, pricing and tough comps. The impact of the pandemic is a little uncertain. We'll talk about that. But ultimately, as we look at the stock, the story from here is, where does diabetes management go over the next 3 years? Over the next 5 years? How important is innovation and access and data? And from our perspective, DexCom has been
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |